Fighting for patient affordability doesn’t necessarily require a scapegoat.
In Search of the ‘Bad Guy’
Related Posts
FDA Accepts Review of Golimumab Biosimilar
Image Credit: Adobe Stock Images/DouceFleur.com The FDA is set to review the Biologics License Applications (BLAs) for Alvotech’s AVT05, a…
How Drug Shortages Are Impacting the European Continent
Studies explore how both the UK and EU are handling these ongoing supply chain challenges. When it comes to mitigation…
Bayer Restructures, Lilly’s Oral GLP-1 Advances, and Court Ruling Shakes Up Obesity Drug Market
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics,…